Results 121 to 130 of about 131,254 (306)

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

Advanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten, Karen Beets, Tessa Schalley, Janne Verreycken, Gayel Duran, Daphne Lintsen, Lisa Schuetz, Xue Zhong, Rinke Nieuwschepen, Melissa Schepers, Brecht Moonen, Jeroen Bogie, Jana Van Broeckhoven, Carlo Heirman, Jurgen Van den Heuvel, Bart Vanderborght, Ismael Varela, Roxanne Nouille, Lotte Jacobs, Jessica Filtjens, Sabah Kasmi, Elise Seynaeve, Veronica Mavrovouna, Jana De Vrieze, Michael A. Brehm, Sandra Maréchal, Sophie Janssens, Florence Lambolez, Niels Hellings, Stefaan De Koker, Bieke Broux   +30 more
wiley   +1 more source

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor

, 2013
Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric ...
CSM Yong (14473233), MA Henderson (14480322), P Neeson (13533949), PK Darcy (14473242), JA Westwood (14473230), MH Kershaw (14473245), CPM Duong (15789299), AJ Davenport (15450752), Liza John (18763624), C Devaud (13423683)   +9 more
core  

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley   +1 more source

Effectors of the Future: Universal Chimeric Antigen Receptor

Transfusion Medicine and Hemotherapy
<b><i>Background:</i></b> Cellular therapies leveraging genetically engineered immune effector cells have witnessed a remarkable surge in success, particularly evident in the notable high rates of remission induction and durable remissions observed in a substantial proportion of heavily pretreated patients with refractory B ...
Schlegel, Lara Sophie, Schlegel, Patrick
openaire   +2 more sources

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source

Recent advances in adoptive cell therapy for cancer immunotherapy

Frontiers in Immunology
Adoptive cell therapy (ACT), a key direction in tumor immunotherapy, has achieved remarkable progress in recent years. This paper systematically reviews the current status and future trends of ACT, covering lymphokine-activated killer cells (LAK), tumor ...
Jiameng Qian, Jiameng Qian, Yuhua Liu, Yuhua Liu   +3 more
doaj   +1 more source

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor.

, 2014
Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen ...
P Darcy (18763603), D Gilham (18763600), Tess Chee (13027890), Liza Raymond (13082100)   +3 more
core  

Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells

Lymph nodes are crucial organs of the adaptive immune system, orchestrating T cell priming, activation and tolerance. T cell activity and function are highly regulated by lymph nodes, which have a unique structure harbouring distinct cells that work ...
Zhou, Ruyi, Zhu, Chaojie, Ding, Yuan, Wang, Weilin, Mao, Zhengwei, Chen, Dong, Shen, Xinyuan, Li, Hongjun, Liang, Xiao, Wu, Wei, Yao, Yuejun, Fang, Weijia, Dotti, Gianpietro, Sun, Jie, Liao, Ziyan, Gu, Zhen, Sheng, Tao, Liu, Feng, Shi, Jiaqi, Wang, Yanfang, Zhao, Peng, Wu, Qing   +21 more
core   +2 more sources